Sumitomo Corporation of Americas completed the acquisition of 20% stake in Upsher-Smith Laboratories, LLC from Sawai Pharmaceutical Co., Ltd.
January 03, 2018
Share
Sumitomo Corporation of Americas agreed to acquire 20% stake in Upsher-Smith Laboratories, LLC from Sawai Pharmaceutical Co., Ltd. (TSE:4555) for approximately $210 million on November 13, 2017. The consideration is subject to adjustments. Upsher-Smith Laboratories reported net sales of $397 million in 2016. The transaction is expected to close by the end of March 2018. Debevoise & Plimpton LLP acted as legal advisor for Sawai Pharmaceutical. The Debevoise team is led by partner Andrew L. Bab and includes partner Gary M. Friedman, associates Joseph Binder, David P. Iozzi, David R. Rock, Michael Ronca and international associate Kietaro Hamada.
Sumitomo Corporation of Americas completed the acquisition of 20% stake in Upsher-Smith Laboratories, LLC from Sawai Pharmaceutical Co., Ltd. (TSE:4555) on January 3, 2018.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
SAWAI GROUP HOLDINGS CO., LTD. 
